TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35994794

Group type: COMPARATOR
Intervention: Stable weight or gain
Number of subjects: 3504

Group type: COMPARATOR
Intervention: <5% weight loss
Number of subjects: 3504

Group type: COMPARATOR
Intervention: ≥5% weight loss
Number of subjects: 3504
Study: 34473018

Group type: EXPERIMENTAL
Intervention: Cardiac surgery (CABG, isolated mitral valve, isolated aortic valve, combined surgical procedures)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Preoperative preparation time ≤2 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Body surface area (BSA) <1.85 m2
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Newly developing atrial fibrillation (AF)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: History of previous cerebrovascular events
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Total anterior circulation infarction (TACI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Partial anterior circulation infarction (PACI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Posterior circulation infarction (POCI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cortical border zone infarction (CBZI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined POCI + CBZI
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Multiple territorial infarcts (MTI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lacunar circulation infarction (LACI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale following AIS
Number of subjects: 49
Study: 32938410

Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Active placebo control
Number of subjects: 88
Study: 36155369

Group type: EXPERIMENTAL
Intervention: Buprenorphine patch (5 mcg every hour)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tramadol injections (100 mg every 8 hours)
Number of subjects: 150
Study: 33415357

Group type: EXPERIMENTAL
Intervention: Alternate part-time patching
Number of subjects: 76

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 76
Study: 35975404

Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg once daily for 12 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg
Number of subjects: 222
Study: 33624862

Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical framework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohort study, multi-centre case control study, randomised clinical trial
Number of subjects: 0
Study: 32321085

Group type: EXPERIMENTAL
Intervention: Mindfulness-integrated cognitive behavior therapy (MICBT)
Number of subjects: 20
Study: 34973410

Group type: EXPERIMENTAL
Intervention: Website-based learning contents for ADR monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Small notebook for monitoring ADRs
Number of subjects: 60
Study: 34011049

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion treatment for ankylosing spondylitis for 30 days followed by a 6-month follow-up.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific intervention details not provided).
Number of subjects: 0
Study: 33211166

Group type: EXPERIMENTAL
Intervention: Functional class I or II
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Distance (6MWD) ≥ 380 m
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Distance (6MWD) ≥ 440 m
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Cardiac index > 2.5 L/min/m2
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Functional class I or II and 6MWD ≥ 440 m
Number of subjects: 563
Study: 35212235

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine 84 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo baseline SDLP
Number of subjects: 27
Study: 34246251

Group type: EXPERIMENTAL
Intervention: Non-opioid prescription
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 33017662

Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 367

Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 367
Study: 35768915

Group type: EXPERIMENTAL
Intervention: Community-based intervention (CBI) including nurse training/mentorship, health education by village health workers, adherence support, and multidisciplinary team meetings
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Community-based intervention (CBI)
Number of subjects: 547
Study: 33638646

Group type: EXPERIMENTAL
Intervention: 125I seeds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hookwire localization
Number of subjects: 0

Group type: COMPARATOR
Intervention: 125I seeds vs Hookwire localization
Number of subjects: 0
Study: 32407242

Group type: EXPERIMENTAL
Intervention: Oral ketone ester (KE) intake (60 g carbohydrates/h combined with three boluses of 25, 20, and 20 g (R)-3-hydroxybutyl (R)-3-hydroxybutyrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control drink (CON)
Number of subjects: 12
Study: 36302570

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34690339

Group type: EXPERIMENTAL
Intervention: Short-term-focused training on the Tuebingen trainer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nontrainee group (control)
Number of subjects: 18
Study: 35754043

Group type: EXPERIMENTAL
Intervention: Suture group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Without Suture group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 100
Study: 33305513

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (target dose 97/103 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: valsartan (target dose 160 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 0
Study: 36427015

Group type: EXPERIMENTAL
Intervention: Hip Arthroscopy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 99
Study: 33650839

Group type: EXPERIMENTAL
Intervention: Self‐Paced Walking Test (SPWT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Swiss Spinal Stenosis Questionnaire (SSS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI)
Number of subjects: 180
Study: 34906007

Group type: EXPERIMENTAL
Intervention: Transcultural Nursing Course (TNC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no TNC)
Number of subjects: 100
Study: 34148852

Group type: EXPERIMENTAL
Intervention: Extended cervical laminoplasty with unilateral C4-5 foraminotomy
Number of subjects: 20
Study: 32779826

Group type: EXPERIMENTAL
Intervention: Over-the-phone supportive care tailored to the needs of oral cancer patients, provided by a health professional
Number of subjects: 25
Study: 34339490

Group type: EXPERIMENTAL
Intervention: Peer-led intervention (Young & Active) facilitated by peer mentors (PMs) during the school year 2016-2017.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peer-led intervention (Young & Active) facilitated by peer mentors (PMs).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (15 control schools).
Number of subjects: 30
Study: 35148541

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 80

Group type: COMPARATOR
Intervention: No clipping
Number of subjects: 80
Study: 33227441

Group type: EXPERIMENTAL
Intervention: 42.6 Gy in 10 fractions (Fx)
Number of subjects: 32
Study: 35912711

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 804

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Peak C-reactive protein (CRP)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Nadir platelet count
Number of subjects: 804
Study: 33984691

Group type: EXPERIMENTAL
Intervention: Having a partner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-partnered persons
Number of subjects: 0
Study: 35850030

Group type: EXPERIMENTAL
Intervention: Finger exercise
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 232
Study: 34186135

Group type: EXPERIMENTAL
Intervention: Annual prostate-specific antigen (PSA) tests for 6 years and digital rectal exams (DRE) for 4 years
Number of subjects: 2855

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 2855
Study: 35487546

Group type: EXPERIMENTAL
Intervention: CombinADO intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Media campaign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toolkit for providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer-support groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support groups for parents/caregivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discreet pill containers
Number of subjects: 0
Study: 32330670

Group type: EXPERIMENTAL
Intervention: TACTICS implementation (context-tailored implementation approach) after provider training in prolonged exposure therapy (PE) for PTSD.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provider training in prolonged exposure therapy (PE) alone.
Number of subjects: 0
Study: 36159368

Group type: EXPERIMENTAL
Intervention: Prepectoral implant placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subpectoral implant placement
Number of subjects: 0
Study: 32902856

Group type: EXPERIMENTAL
Intervention: Smoking Relapse Prevention (SRP) intervention including a targeted educational DVD and a validated self-help intervention
Number of subjects: 412

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Smoking Relapse Prevention (SRP) intervention
Number of subjects: 412
Study: 36260465

Group type: EXPERIMENTAL
Intervention: Behavior modification using a self-designed dental storybook
Number of subjects: 380

Group type: COMPARATOR
Intervention: Behavior modification without storybook
Number of subjects: 380
Study: 34162912

Group type: EXPERIMENTAL
Intervention: Apology (yes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apology (no)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High relationship value
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low relationship value
Number of subjects: 0
Study: 33002131

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard anticoagulants
Number of subjects: 126
Study: 36263035

Group type: EXPERIMENTAL
Intervention: Slow-paced breathing (4sec inhalation, 6sec exhalation for 20 minutes 3x daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Slow-paced breathing (dose-response relationship)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Slow-paced breathing
Number of subjects: 46
Study: 32316765

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Waiting List Control (WL)
Number of subjects: 66
Study: 32131866

Group type: EXPERIMENTAL
Intervention: IC43 100 μg
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 800
Study: 34232458

Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography (cEEG) monitoring initiated on admission to intensive care, with a focus on the burden of ictal‐interictal continuum (IIC) patterns, including seizures.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Severe ictal‐interictal continuum (IIC) patterns identified through cEEG monitoring.
Number of subjects: 142
Study: 33168128

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) supplementation
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 34896412

Group type: EXPERIMENTAL
Intervention: Vancomycin-soaked sponges
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Saline-soaked sponges (Control)
Number of subjects: 1037
Study: 33839603

Group type: EXPERIMENTAL
Intervention: pembrolizumab + chemotherapy
Number of subjects: 59
Study: 32826103

Group type: EXPERIMENTAL
Intervention: Accelerated individually randomized RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled human challenge trials (CHI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wide distribution through emergency use authorization
Number of subjects: 0
Study: 35855386

Group type: EXPERIMENTAL
Intervention: Citrus aurantium essential oil (5 drops, twice a day for one month)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (twice a day for one month)
Number of subjects: 68
Study: 33954198

Group type: EXPERIMENTAL
Intervention: PECS II (0.5% ropivacaine 25 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 40
Study: 36209104

Group type: EXPERIMENTAL
Intervention: Integrated care intervention (add-on intervention)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Integrated care intervention
Number of subjects: 197
Study: 33939376

Group type: EXPERIMENTAL
Intervention: Mindful yoga intervention (9 weeks)
Number of subjects: 11
Study: 32971764

Group type: EXPERIMENTAL
Intervention: Chewing exerciser (CE) in addition to conventional physiotherapy (PT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional physiotherapy (PT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chewing exerciser (CE)
Number of subjects: 22
Study: 35616436

Group type: EXPERIMENTAL
Intervention: Naltrexone and acamprosate (alone and in combination)
Number of subjects: 1168
Study: 33132018

Group type: EXPERIMENTAL
Intervention: FFC‐AL‐EIT intervention
Number of subjects: 794
Study: 33127637

Group type: EXPERIMENTAL
Intervention: Proactive telephone-based peer support
Number of subjects: 501
Study: 35614292

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 34898563

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2745

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 2745
Study: 616636432

Group type: EXPERIMENTAL
Intervention: Science to Service Laboratory (SSL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Training as Usual (TAU)
Number of subjects: 60
Study: 32785710

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 0.5 mg/kg intravenously twice daily for 5 days
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 393
Study: 35303894

Group type: EXPERIMENTAL
Intervention: High-intensity strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity strategies
Number of subjects: 0
Study: 32188386

Group type: EXPERIMENTAL
Intervention: Established markers of inflammation (e.g., C-reactive protein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer inflammatory markers (e.g., lipoprotein-associated phospholipase A2, cytokines, myeloperoxidase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory and pleiotropic drugs
Number of subjects: 0
Study: 32438719

Group type: EXPERIMENTAL
Intervention: Combination of grapefruit, bitter orange, and olive extracts for eight weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 32684076

Group type: EXPERIMENTAL
Intervention: Video-guided exercise intervention
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 14
Study: 32846424

Group type: COMPARATOR
Intervention: Peptide phage display approach using serum samples from patients
Number of subjects: 4

Group type: COMPARATOR
Intervention: Peptide phage display approach
Number of subjects: 4
Study: 33238154

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 32444161

Group type: EXPERIMENTAL
Intervention: Mobile phone app
Number of subjects: 128

Group type: COMPARATOR
Intervention: Telephone assistance
Number of subjects: 128
Study: 35130492

Group type: EXPERIMENTAL
Intervention: Outpatient palliative care intervention (n=61)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (n=59)
Number of subjects: 120
Study: 32398848

Group type: EXPERIMENTAL
Intervention: Localized intraoperative laser retinopexy
Number of subjects: 93

Group type: COMPARATOR
Intervention: 360° intraoperative laser retinopexy
Number of subjects: 93
Study: 35894768

Group type: EXPERIMENTAL
Intervention: Routine hypoglycemic drugs + resistance training (AE + RT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine hypoglycemic drugs
Number of subjects: 30
Study: 33771645

Group type: EXPERIMENTAL
Intervention: Mobile management (MM)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard management (SM)
Number of subjects: 309
Study: 35894993

Group type: EXPERIMENTAL
Intervention: Midfoot joint mobilization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 20
Study: 34128724

Group type: EXPERIMENTAL
Intervention: Deep learning (DL) reconstruction of accelerated bSSFP cardiac MRI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balanced steady-state free precession (bSSFP) MRI
Number of subjects: 50
Study: 32087336

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) tool provided to primary care clinicians (PCPs) and psychiatrists during patient visits.
Number of subjects: 10347

Group type: EXPERIMENTAL
Intervention: Access to CDS tool for PCPs and psychiatrists.
Number of subjects: 10347

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10347
Study: 36287634

Group type: EXPERIMENTAL
Intervention: Endometrial Scratching (ES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no Endometrial Scratching)
Number of subjects: 0
Study: 35585475

Group type: EXPERIMENTAL
Intervention: Education + Media + PN
Number of subjects: 428

Group type: COMPARATOR
Intervention: Education + Media
Number of subjects: 428
Study: 33499570

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) treatment every 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) treatment every 2 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) treatment every 3 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) treatment every 4 weeks
Number of subjects: 20
Study: 36385466

Group type: EXPERIMENTAL
Intervention: OT-guided cognitive intervention protocol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard delirium prevention protocol
Number of subjects: 70
Study: 34284099

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in poor CYP2D6 metabolizers
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in intermediate CYP2D6 metabolizers
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in normal CYP2D6 metabolizers
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in ultrarapid CYP2D6 metabolizers
Number of subjects: 1440
Study: 35162842

Group type: EXPERIMENTAL
Intervention: Submucosal intralesional injections of dexamethasone (2 mL; 4 gm/mL)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Hyaluronidase (1500 IU)
Number of subjects: 130
Study: 34541864

Group type: EXPERIMENTAL
Intervention: TARE plus chemotherapy
Number of subjects: 428

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 428
Study: 34924512

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral-Based Physical Therapy (CBPT-Trauma)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Education program
Number of subjects: 325
Study: 32631130

Group type: EXPERIMENTAL
Intervention: Mobile interventionist approach as an add-on to assertive community treatment (ACT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Assertive community treatment (ACT) alone
Number of subjects: 49
Study: 35552458

Group type: EXPERIMENTAL
Intervention: Precision prevention materials incorporating MC1R genetic risk (higher/average)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Generic prevention (standard) materials
Number of subjects: 1134
Study: 33965364

Group type: EXPERIMENTAL
Intervention: Online weight management platform with weekly coaching calls (weeks 1–12) tapered to bi-weekly calls (weeks 12–24)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comparison group (no access to online platform or coaching calls)
Number of subjects: 35
Study: 32907547

Group type: EXPERIMENTAL
Intervention: BELIEF protocol (two face-to-face counseling sessions at 24 and 34 weeks of pregnancy, plus eight weekly telephone counseling sessions)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BELIEF protocol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (received only prenatal routine care)
Number of subjects: 80
Study: 35641889

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered Intensive Sleep Retraining (ISR)
Number of subjects: 12
Study: 33991186

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 877

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 877
Study: 32290815

Group type: EXPERIMENTAL
Intervention: HABIT-ILE (50 hours over two weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual motor activity (including regular rehabilitation)
Number of subjects: 50
Study: 35158444

Group type: EXPERIMENTAL
Intervention: Random Forest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ridge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LASSO
Number of subjects: 0
Study: 33981369

Group type: EXPERIMENTAL
Intervention: Probiotic supplement preparation (PSP)
Number of subjects: 120
Study: 32090630

Group type: EXPERIMENTAL
Intervention: RT‐HIIT
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: AT‐HIIT
Number of subjects: 240

Group type: COMPARATOR
Intervention: UC
Number of subjects: 240
Study: 36152764

Group type: EXPERIMENTAL
Intervention: 25% IV albumin 1.5 g/kg weekly infusions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 48